Relative Strength Chart Akeso, Inc.

Equities

Delayed Hong Kong S.E. Other stock markets 06:50:02 13/02/2026 am IST			5-day change	1st Jan Change
102.20 ^HKD	-1.45%		+0.89%	-9.56%

06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI
03/02	Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical	RE

End-of-day quotes

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	AKESO, INC.	Bio Therapeutic Drugs	-1.45%	+0.89%	-9.56%	+74.70%	+68.23%	1.24TCr